Quantifying the benefits of remission duration in focal and segmental glomerulosclerosis.

ABSTRACT:

Background

Although the clinical benefit of obtaining a remission in proteinuria in nephrotic patients with focal segmental glomerulosclerosis (FSGS) is recognized, the long-term value of maintaining it and the impact of relapses on outcome are not well described.

Methods

We examined the impact of remissions and relapses on either a 50% decline in kidney function or end-stage kidney disease (combined event) using time-dependent and landmark analyses in a retrospective study of all patients from the Toronto Glomerulonephritis Registry with biopsy-proven FSGS, established nephrotic-range proteinuria and at least one remission.

Results

In the 203 FSGS individuals with a remission, 89 never relapsed and 114 experienced at least one relapse. The first recurrence was often

SUBMITTER: Jauhal A 

PROVIDER: S-EPMC10064837 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature